Cargando…

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI

OBJECTIVES: SMT19969 is a novel narrow-spectrum antimicrobial under development for the treatment of Clostridium difficile infection (CDI). The objectives were to assess the relative efficacies of SMT19969, vancomycin and fidaxomicin in the hamster model of CDI. METHODS: Hamsters were infected with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sattar, Abdul, Thommes, Pia, Payne, Lloyd, Warn, Peter, Vickers, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498292/ https://www.ncbi.nlm.nih.gov/pubmed/25652749 http://dx.doi.org/10.1093/jac/dkv005

Ejemplares similares

In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection
por: Weiss, William, et al.
Publicado: (2014)

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile
por: Corbett, D., et al.
Publicado: (2015)

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
por: Freeman, Jane, et al.
Publicado: (2015)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

1952. Evaluation of Relapse and Reinfection Using Whole-Genome Sequencing of Clostridium difficile Isolates From Elderly Patients With C. difficile Infection (CDI) in the EXTEND Randomized, Controlled, Comparative Study of Extended-Pulsed Fidaxomicin and Vancomycin for the Treatment of CDI
por: Wilcox, Mark, et al.
Publicado: (2018)

A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
por: Watt, Maureen, et al.
Publicado: (2016)

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
por: Baines, S. D., et al.
Publicado: (2015)

New advances in the treatment of Clostridium difficile infection (CDI)
por: Hedge, Dennis D, et al.
Publicado: (2008)

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
por: Vehreschild, Maria J. G. T., et al.
Publicado: (2018)

1653 Results of a Treatment Protocol Encouraging First-Line Use of Fidaxomicin for Select Patients with Clostridium difficile Infection (CDI)
por: Navalkele, Bhagyashri, et al.
Publicado: (2014)

Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
por: Vehreschild, Maria J. G. T., et al.
Publicado: (2018)

Use of Electronic Data to Identify Risk Factors Associated with Clostridium difficile Infection (CDI) and to Develop CDI Risk Scores
por: Aukes, Laurie, et al.
Publicado: (2017)

1980. Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed Clostridium Difficile Infection (CDI)
por: Tirmizi, Samad, et al.
Publicado: (2018)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

2365. Volatile Metabolite-Based Detection of Clostridium difficile Infection (CDI)
por: Aloum, Obadah, et al.
Publicado: (2019)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN)
por: Paul, Sumita, et al.
Publicado: (2019)

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

527 Age-Related Changes in the Incidence of Community-Associated Clostridium Difficile Infection (CDI)
por: Faden, Howard
Publicado: (2014)

485. On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired Clostridium difficile Infection (CDI)
por: Stevens, Vanessa, et al.
Publicado: (2018)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI
por: Navalkele, Bhagyashri D., et al.
Publicado: (2016)

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018
por: Viprey, Virginie F, et al.
Publicado: (2022)

973 Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients
por: Stevens, Vanessa, et al.
Publicado: (2014)

467. Investigation of a Clostridium difficile Infection (CDI) Outbreak in a Community Teaching Hospital
por: Parker, Laura, et al.
Publicado: (2018)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
por: Duperchy, Esther, et al.
Publicado: (2018)

1635 A Retrospective Study Comparing Outcomes of Present on Admission Clostridium difficile Infection (CDI) vs Non-present on Admission CDI at a Tertiary-care Hospital in Detroit
por: Awali, Reda A., et al.
Publicado: (2014)

Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study
por: Swale, Andrew, et al.
Publicado: (2014)

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
por: Fareed, Shaaz, et al.
Publicado: (2018)

Are Patients with Prior Clostridium difficile Infection (CDI) a Potential Source of Transmission during Hospital Admissions?
por: Gonzalez-Orta, Melany, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_33cs2vbd4etg37md3s2fg9192j